This brand name is authorized in Ecuador, Estonia, Lithuania, Poland.
The drug XALOPTIC contains one active pharmaceutical ingredient (API):
1
|
UNII
6Z5B6HVF6O - LATANOPROST
|
|
The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01EE01 | Latanoprost | S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 3058-MEE-1017 |
| EE | Ravimiamet | 1300071, 1601884 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1005360, 1068514 |
| PL | Rejestru Produktów Leczniczych | 100218380, 100333359, 100340738, 100350441 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.